Karyopharm Proceeds with Myelofibrosis sNDA Submission

Karyopharm Therapeutics reported its second quarter 2026 financial results, highlighting continued progress towards its regulatory milestones for selinexor in the treatment of myelofibrosis. The company expects regulatory authorities to review its supplemental New Drug Application (sNDA).

The sNDA, planned for submission in August 2026 under the Accelerated Approval pathway, is based on positive results from the Phase 3 SENTRY study. Data from this study were presented at both the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) meetings and subsequently published in a peer-reviewed journal.

Karyopharm's financial performance in the second quarter is expected to support ongoing research and development efforts. The company has provided further details on its financial standing and strategic outlook through its investor relations channels.

The company is now focused on engaging with regulatory bodies and preparing for potential market entry. The development of selinexor in combination with ruxolitinib aims to address the unmet need for improved treatment options for patients suffering from myelofibrosis.